ClinicalTrials.gg
CompletedNCT02101268Simplify 2Updated May 23, 2023Results posted

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

A Phase 3 interventional study of Momelotinib and Best Available Therapy (BAT) in Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) and Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), sponsored by Sierra Oncology LLC - a GSK company. Completed at 48 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-23.

Sponsored by Sierra Oncology LLC - a GSK company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing momelotinib in Primary Myelofibrosis — 3 open to participants now, 4 under way, none of them phase 3. momelotinib · Primary Myelofibrosis.

Enrollment
6th of 12
156 · median 138
Started
2014
with 1 other
Phase 3
3 of 12
none open now
Registered
5th of 12
by date
Lead sponsor
8 of 12
Sierra Oncology LLC - a GSK company

Among the 12 studies testing momelotinib in Primary Myelofibrosis, this one is the 6th largest by enrollment, is one of 2 that started in 2014, is one of 3 in phase 3, and was the 5th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

3 of the 12 studies testing momelotinib in Primary Myelofibrosis are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About momelotinib

momelotinib: first FDA approval 2023 (OJJAARA), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing momelotinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This study is to determine the efficacy of momelotinib (MMB) versus best available therapy (BAT) in anemic or thrombocytopenic adults with primary myelofibrosis (PMF), or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) who were treated with ruxolitinib as measured by splenic response rate at Week 24 (SRR24).

Participants will be randomized to receive either MMB or BAT for 24 weeks during the randomized treatment phase, after which they will be eligible to receive MMB in an extended treatment phase for up to an additional 204 weeks. After discontinuation of study medication, assessments will continue for 12 additional weeks, after which participants will be contacted for survival follow-up approximately every 6 months for up to 5 years from the date of enrollment or until study termination. For those subjects planning to continue treatment with MMB following the end of the study, the End of Treatment, 30-day, 12-Week, and survival follow-up visits are not required.

03

Conditions studied

  • Primary Myelofibrosis (PMF)
  • Post-polycythemia Vera (Post-PV)
  • Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Palpable splenomegaly at least 5 cm below left costal margin
  • Confirmed diagnosis of PMF in accordance, or Post-PV/ET MF
  • Currently or previously treated with ruxolitinib for PMF or Post-PV/ET MF for at least 28 days, and characterized by

    • Requirement for RBC transfusion while on ruxolitinib treatment, OR
    • Dose adjustment of ruxolitinib to \< 20 mg twice daily at start of or during ruxolitinib treatment AND at least one of the following while on ruxolitinib treatment:

      • ≥ (CTCAE) Grade 3 thrombocytopenia, OR
      • ≥ CTCAE Grade 3 anemia, OR
      • ≥ CTCAE Grade 3 hematoma (bleed)
  • High risk OR intermediate-2 risk as defined by Dynamic International Prognostic Scoring System (DIPSS), OR intermediate-1 risk as defined by DIPSS and associated with symptomatic splenomegaly, and/or hepatomegaly
  • If receiving myelofibrosis therapy, must be on a stable dose of the same regimen for at least 2 weeks prior to screen date and through the screening period
  • If not receiving myelofibrosis therapy, must remain off therapy for at least 2 weeks prior to screen date and through the screening period
  • Acceptable laboratory assessments obtained within 14 days prior to Randomization

    • (ANC) > 0.75 x 10\^9/L in the absence of growth factor in the prior 7 days
    • Peripheral blood blast count \< 10%
    • (AST) and alanine transaminase (ALT) ≤ 3 x the (ULN) (≤ 5 x ULN if liver is involved by extramedullary hematopoiesis as judged by the investigator or if related to iron chelator therapy that was started within the prior 60 days)
    • Calculated of ≥ 45 mL/min
    • Direct ≤ 2.0 x ULN
  • > 24 weeks
  • Negative serum pregnancy test for female subjects (unless surgically sterile or greater than two years )
  • Males and females of must agree to use protocol-specified method(s) of
  • Females who are nursing must agree to discontinue nursing before the first dose of MMB
  • Able to understand and willing to sign form (ICF)

Key Exclusion Criteria:

  • Prior splenectomy
  • Splenic irradiation within 3 months prior to Randomization
  • Use of agent within 28 days prior to Randomization
  • Prior treatment with MMB
  • Hematopoietic growth factor (granulocyte growth factor, erythropoiesis stimulating agent, thrombopoietin mimetic) within 28 days prior to Randomization
  • Uncontrolled inter-current illness, per protocol
  • Known positive status for (HIV)
  • Chronic active or acute viral hepatitis A, B, or C infection, or or C carrier
  • Presence of peripheral neuropathy ≥ CTCAE Grade 2
  • Unwilling or unable to undergo a MRI or CT Scan per study protocol requirements

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    Arm 1: Momelotinib

    Participants will receive open-label momelotinib for 24 weeks during the randomized treatment phase, after which they will be eligible to receive momelotinib in an extended treatment phase for up to an additional 204 weeks.

    Drug: Momelotinib

  • Active comparator
    Arm 2: Best Available Therapy (BAT)

    Participants in the BAT treatment arm will receive open-label treatment at doses and schedules determined by the investigator in accordance with standard of care. Therapy may be changed at any time during the study except during the screening period. After completion of the randomized treatment phase, participants will be eligible to receive momelotinib for the duration of the study during the extended treatment phase for up to 204 weeks.

    Drug: Best Available Therapy (BAT)

Interventions

  • Momelotinib tablet administered orally once daily

    Also known as: GS-0387, CYT387

  • DrugBest Available Therapy (BAT)

    Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.

06

What researchers measure

Primary outcomes

  1. Splenic Response Rate at Week 24

    Splenic response rate at Week 24 is defined as the percentage of participants who achieved a spleen volume reduction of ≥ 35% from baseline at the Week 24 assessment as measured by MRI or CT.

    Time frame: Week 24

Secondary outcomes

  1. Total Symptom Score (TSS) Response Rate at Week 24

    Total symptom score (TSS) is defined as the percentage of participants who achieved a ≥50% reduction in TSS at Week 24 versus baseline as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) v2.0 diary. Response rate was calculated using the average of the daily TSS from a consecutive 28-day period prior to Week 24, which had ≥20 daily TSS available. The modified MPN-SAF patient-reported outcome instrument consisted of 8 items assessing worst daily incidence of tiredness, filling up quickly, abdominal discomfort, night sweats, itching, bone pain, pain under ribs on left side, and inactivity. Scoring of TSS in this study was based on 7 of these items, (0-70) excluding inactivity. These items assess the impact experienced by the participant in the 24 hours prior to completing the questionnaire. All items are measured using a 0 to 10 Numeric Rating Scale, with 0 corresponding to "Absent" and 10 corresponding to "Worst Imaginable."

    Time frame: Week 24

  2. Rate of Red Blood Cell (RBC) Transfusion in the Randomized Treatment Phase, (the Average Number of RBC Units Transfused Per Month Not Associated With Overt Bleeding)

    Rate of RBC transfusion is defined as the average number of RBC units transfused not associated with clinically overt bleeding per subject-month during the randomized treatment Phase.

    Time frame: Baseline to Week 24

  3. RBC Transfusion Independence Rate at Week 24, (Defined as Absence of RBC Transfusions and no Hemoglobin Level Below 8 g/dL in the 12 Weeks Prior to Week 24, Excluding Cases Associated With Clinically Overt Bleeding)

    RBC transfusion independence rate is the percentage of participants who achieved transfusion independence at Week 24 (responders). RBC transfusion independence is defined as absence of RBC transfusions and no hemoglobin level below 8 g/dL in the 12 weeks prior to Week 24, excluding cases associated with clinically overt bleeding. Transfusion dependence, (non-responder) is defined as at least 4 units of RBC transfusion, or a Hgb level below 8 g/dL, in the 8 weeks prior to week 24. Methods used to assess this outcome measure include collection and recording of any instances of RBC transfusions and collection and recording of any local or central lab hemoglobin measurements

    Time frame: Week 24

  4. RBC Transfusion Dependence Rate at Week 24

    RBC transfusion dependence is the percentage of participants who are transfusion dependent at Week 24, defined as at least 4 units of RBC transfusions, or a hemoglobin level below 8 g/dL in the 8 weeks prior to Week 24, excluding cases associated with clinically overt bleeding.

    Time frame: Week 24

07

Results

Posted May 23, 2023
Limitations and caveats
Best available therapy could also include the approved JAK inhibitor, ruxolitinib, and 88% of participants in the BAT arm continued to receive ruxolitinib.

Participant flow

156 participants were randomized at 52 centers in 8 countries.

Randomized Treatment Phase
Participant flow — Randomized Treatment Phase
MilestoneMomelotinib (MMB)Best Available Therapy (BAT)MMB to MMBBAT to MMB
Started1045200
Completed774100
Not completed271100
Withdrew: Subject decision8400
Withdrew: Physician decision4100
Withdrew: Symptomatic spleen growth0100
Withdrew: Adverse event6000
Withdrew: Death5400
Withdrew: Disease progression4100
Extended Treatment Phase
Participant flow — Extended Treatment Phase
MilestoneMomelotinib (MMB)Best Available Therapy (BAT)MMB to MMBBAT to MMB
Started006440
Completed0000
Not completed006440
Withdrew: Subject decision0032
Withdrew: Physician decision0052
Withdrew: Adverse event001418
Withdrew: Death0051
Withdrew: Transferred to study sra-mmb-436500157
Withdrew: Disease progression00136
Withdrew: Lack of efficacy0094

Outcome measures

PrimarySplenic Response Rate at Week 24

Splenic response rate at Week 24 is defined as the percentage of participants who achieved a spleen volume reduction of ≥ 35% from baseline at the Week 24 assessment as measured by MRI or CT.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Splenic Response Rate at Week 24
ParticipantsMomelotinib (MMB)Best Available Therapy (BAT)
Responder73
Nonresponder9749
Statistical analysis
  • Momelotinib (MMB) vs Best Available Therapy (BAT) · Cochran-Mantel-Haenszel · p = 0.90 · Proportion difference - stratified cmh: 0.01 · 95% CI -0.09 to 0.10
SecondaryTotal Symptom Score (TSS) Response Rate at Week 24

Total symptom score (TSS) is defined as the percentage of participants who achieved a ≥50% reduction in TSS at Week 24 versus baseline as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) v2.0 diary. Response rate was calculated using the average of the daily TSS from a consecutive 28-day period prior to Week 24, which had ≥20 daily TSS available. The modified MPN-SAF patient-reported outcome instrument consisted of 8 items assessing worst daily incidence of tiredness, filling up quickly, abdominal discomfort, night sweats, itching, bone pain, pain under ribs on left side, and inactivity. Scoring of TSS in this study was based on 7 of these items, (0-70) excluding inactivity. These items assess the impact experienced by the participant in the 24 hours prior to completing the questionnaire. All items are measured using a 0 to 10 Numeric Rating Scale, with 0 corresponding to "Absent" and 10 corresponding to "Worst Imaginable."

Time frame:
Week 24
Reported as:
Count of participants · Participants
Total Symptom Score (TSS) Response Rate at Week 24
ParticipantsMomelotinib (MMB)Best Available Therapy (BAT)
Responder273
Nonresponder7648
Statistical analysis
  • Momelotinib (MMB) vs Best Available Therapy (BAT) · Cochran-Mantel-Haenszel · p = < 0.001 · Proportion difference - stratified cmh: 0.20 · 95% CI 0.09 to 0.32
SecondaryRate of Red Blood Cell (RBC) Transfusion in the Randomized Treatment Phase, (the Average Number of RBC Units Transfused Per Month Not Associated With Overt Bleeding)

Rate of RBC transfusion is defined as the average number of RBC units transfused not associated with clinically overt bleeding per subject-month during the randomized treatment Phase.

Time frame:
Baseline to Week 24
Reported as:
Median · units/month
Rate of Red Blood Cell (RBC) Transfusion in the Randomized Treatment Phase, (the Average Number of RBC Units Transfused Per Month Not Associated With Overt Bleeding)
units/monthMomelotinib (MMB)Best Available Therapy (BAT)
Rate of Red Blood Cell (RBC) Transfusion in the Randomized Treatment Phase, (the Average Number of RBC Units Transfused Per Month Not Associated With Overt Bleeding)0.5 (0.0 to 2.4)1.2 (0.0 to 2.8)
Statistical analysis
  • Momelotinib (MMB) vs Best Available Therapy (BAT) · Negative Binomial Model, Adjusted · p = 0.38 · Rate ratio: 0.80 · 95% CI 0.49 to 1.31A smaller ratio represents larger benefit.
SecondaryRBC Transfusion Independence Rate at Week 24, (Defined as Absence of RBC Transfusions and no Hemoglobin Level Below 8 g/dL in the 12 Weeks Prior to Week 24, Excluding Cases Associated With Clinically Overt Bleeding)

RBC transfusion independence rate is the percentage of participants who achieved transfusion independence at Week 24 (responders). RBC transfusion independence is defined as absence of RBC transfusions and no hemoglobin level below 8 g/dL in the 12 weeks prior to Week 24, excluding cases associated with clinically overt bleeding. Transfusion dependence, (non-responder) is defined as at least 4 units of RBC transfusion, or a Hgb level below 8 g/dL, in the 8 weeks prior to week 24. Methods used to assess this outcome measure include collection and recording of any instances of RBC transfusions and collection and recording of any local or central lab hemoglobin measurements

Time frame:
Week 24
Reported as:
Count of participants · Participants
RBC Transfusion Independence Rate at Week 24, (Defined as Absence of RBC Transfusions and no Hemoglobin Level Below 8 g/dL in the 12 Weeks Prior to Week 24, Excluding Cases Associated With Clinically Overt Bleeding)
ParticipantsMomelotinib (MMB)Best Available Therapy (BAT)
Responder4511
Nonresponder5941
Statistical analysis
  • Momelotinib (MMB) vs Best Available Therapy (BAT) · Cochran-Mantel-Haenszel · p = 0.001 · Proportion difference - stratified cmh: 0.23 · 95% CI 0.09 to 0.37A larger proportion represents larger benefit.
SecondaryRBC Transfusion Dependence Rate at Week 24

RBC transfusion dependence is the percentage of participants who are transfusion dependent at Week 24, defined as at least 4 units of RBC transfusions, or a hemoglobin level below 8 g/dL in the 8 weeks prior to Week 24, excluding cases associated with clinically overt bleeding.

Time frame:
Week 24
Reported as:
Count of participants · Participants
RBC Transfusion Dependence Rate at Week 24
ParticipantsMomelotinib (MMB)Best Available Therapy (BAT)
Dependent5233
Nondependent5219
Statistical analysis
  • Momelotinib (MMB) vs Best Available Therapy (BAT) · Cochran-Mantel-Haenszel · p = 0.10 · Proportion difference - stratified cmh: -0.13 · 95% CI -0.29 to 0.03A smaller proportion represents larger benefit.

Adverse events

Collected over Serious and other Adverse events were recorded that occurred from initiation of investigational product (IP) until 30 days after the last administration of IP regardless of cause or relationship. Serious events are monitored up to 12 weeks and all-cause mortality was assessed for up to 5 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Momelotinib (MMB)8/104 (7.7%)37/104 (35.6%)99/104 (95.2%)
Best Available Therapy (BAT)5/52 (9.6%)12/52 (23.1%)46/52 (88.5%)
MMB to MMB29/64 (45.3%)33/64 (51.6%)63/64 (98.4%)
BAT to MMB18/40 (45%)19/40 (47.5%)40/40 (100%)
Most frequent serious events
Showing 10 of 122
Most frequent serious events
EventMomelotinib (MMB)Best Available Therapy (BAT)MMB to MMBBAT to MMB
AnaemiaBlood and lymphatic system disorders4/1040/521/644/40
PneumoniaInfections and infestations2/1041/526/641/40
Splenic infarctionBlood and lymphatic system disorders0/1040/520/643/40
PyrexiaGeneral disorders2/1040/522/643/40
SepsisInfections and infestations2/1042/524/641/40
Cardiac failureCardiac disorders3/1041/521/642/40
HyponatraemiaMetabolism and nutrition disorders0/1040/520/642/40
Confusional statePsychiatric disorders0/1040/520/642/40
Abdominal painGastrointestinal disorders0/1042/520/640/40
General physical health deteriorationGeneral disorders2/1042/520/640/40
Most frequent other events
Showing 10 of 75
Most frequent other events
EventMomelotinib (MMB)Best Available Therapy (BAT)MMB to MMBBAT to MMB
DiarrhoeaGastrointestinal disorders33/1048/5219/6410/40
AstheniaGeneral disorders20/10411/528/6411/40
ThrombocytopeniaBlood and lymphatic system disorders18/1046/528/6411/40
CoughRespiratory, thoracic and mediastinal disorders18/1046/5217/648/40
PyrexiaGeneral disorders13/1044/5216/6410/40
AnaemiaBlood and lymphatic system disorders15/10410/5214/646/40
Urinary tract infectionInfections and infestations11/1044/528/648/40
NauseaGastrointestinal disorders20/1045/528/645/40
FatigueGeneral disorders16/10410/527/647/40
Peripheral sensory neuropathyNervous system disorders7/1040/526/647/40

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Momelotinib (MMB)Best Available Therapy (BAT)Total
<=18 years000
Between 18 and 65 years411455
>=65 years6338101
Age, Continuous
Age, Continuous(years)Momelotinib (MMB)Best Available Therapy (BAT)Total
Median67.0 (41 to 92)69.5 (52 to 82)68.0 (41 to 92)
Sex: Female, Male
Sex: Female, Male(Participants)Momelotinib (MMB)Best Available Therapy (BAT)Total
Female352863
Male692493
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Momelotinib (MMB)Best Available Therapy (BAT)Total
Hispanic or Latino549
Not Hispanic or Latino8140121
Unknown or Not Reported18826
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Momelotinib (MMB)Best Available Therapy (BAT)Total
White8344127
Black or African American606
Not Permitted15823
Transfusion Dependent
Transfusion Dependent(Participants)Momelotinib (MMB)Best Available Therapy (BAT)Total
Yes582785
No462571
Total Symptom Score (TSS)
Total Symptom Score (TSS)(Participants)Momelotinib (MMB)Best Available Therapy (BAT)Total
< 18612889
>= 18432467
Weight
Weight(kg)Momelotinib (MMB)Best Available Therapy (BAT)Total
Median75.4 (68.0 to 87.0)74.0 (62.0 to 81.3)75.0 (66.0 to 85.7)

3 further baseline measures are reported on the registry.

08

Study locations

48 sites
  • Los Angeles, California, United States
  • Gainesville, Florida, United States
  • Atlanta, Georgia, United States
  • Kansas City, Kansas, United States
  • Baltimore, Maryland, United States
  • Saint Louis, Missouri, United States
  • Albuquerque, New Mexico, United States
  • New York, New York, United States
  • Durham, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Cleveland, Ohio, United States
  • Pittsburgh, Pennsylvania, United States
  • Houston, Texas, United States
  • Edmonton, Alberta, Canada
  • Montreal, Canada
  • Toronto, Canada
  • Lille cedex, France
  • Marseille, France
  • Nantes, France
  • Paris, France
  • Pierre Benite Cedex, France
  • Toulouse, France
  • Villejuif Cedex, France
  • Dresden, Germany
  • Hamburg, Germany
  • Koln, Germany
  • Mannheim, Germany
  • Ashkelon, Israel
  • Haifa, Israel
  • Jerusalem, Israel
  • Tel-Aviv, Israel
  • Bologna, Italy
  • Firenze, Italy
  • Genova, Italy
  • Milano, Italy
  • Novara, Italy
  • Roma, Italy
  • Varese, Italy
  • Badalona, Spain
  • Barcelona, Spain
  • Madrid, Spain
  • Salamanca, Spain
  • Valencia, Spain
  • Zaragoza, Spain
  • Birmingham, England, United Kingdom
  • Leeds, England, United Kingdom
  • Leicester, England, United Kingdom
  • London, England, United Kingdom
09

References and documents

Publications

  • Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018 Feb;5(2):e73-e81. doi: 10.1016/S2352-3026(17)30237-5. Epub 2017 Dec 20. PubMed 29275119 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Jul 2016, 25 months.

Results were first posted in May 2023, 6 years 9 months after primary completion. A results delay was requested in Jan 2017.

Of 22 phase 3 interventional studies under Primary Myelofibrosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 68. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2014
First posted
Apr 2, 2014
StartActual
Jun 19, 2014
Primary completionActual
Jul 28, 2016
CompletionActual
Apr 25, 2019
Results delay requested
Jan 5, 2017
Results first posted
May 23, 2023
Last update
May 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02101268
Responsible party
Sponsor
First posted
Apr 2, 2014
Start date
Jun 19, 2014
Primary completion
Jul 28, 2016
Completion
Apr 25, 2019
Results posted
May 23, 2023
Last update
May 23, 2023

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Momelotinib

Start the discussion